We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antithrombin III infusion improves anticoagulation in congenital diaphragmatic hernia patients on extracorporeal membrane oxygenation.
- Authors
Perry, Tanya; Henry, Brandon; Cooper, David S; Keswani, Sundeep G; Burton, Kimberly S; Lim, Foong-Yen; Chernoguz, Artur; Frischer, Jason S
- Abstract
Purpose: Achieving effective anticoagulation during neonatal extracorporeal membrane oxygenation (ECMO) without increasing the risk of hemorrhage remains challenging. The use of antithrombin III (AT-III) for this purpose has been examined, but studies have been limited to intermittent bolus dosing. We aimed to evaluate the efficacy and safety of an institutionally developed AT-III continuous infusion protocol in neonates receiving ECMO for the treatment of congenital diaphragmatic hernia (CDH). Methods: In this single center, retrospective study, all neonates with a CDH who received ECMO support during the study period were included. Data on anticoagulation labs and therapy, life-threatening bleeding, and circuit changes were analyzed. Results: Eleven patients were divided into two groups: patients with AT-III continuous infusion (n = 5) and without (n = 6). There were no differences in the gestational age (p = 0.29), sex (p = 1.00), ECMO duration (p = 0.59), or initial AT-III levels (p = 0.76) between groups. Patients in the AT-III infusion group had on average 18.5% higher AT-III levels (p < 0.0001). Patients receiving continuous AT-III infusions spent a significantly higher percentage of ECMO time within the therapeutic range, measured using anti-Factor Xa levels (64.9±4.2% vs. 29.1±8.57%, p = 0.008), and required fewer changes to the heparin infusion rate (6.48±0.88 vs 2.38±0.36 changes/day changes/day, p = 0.005). Multivariate analysis revealed continuous infusion of AT-III did not increase the rate of intracranial or surgical bleeding (p = 0.27). Conclusion: AT-III as a continuous infusion in CDH neonates on ECMO provides a decreased need to modify heparin infusion and more consistent therapeutic anticoagulation without increasing the risk of life-threatening bleeding.
- Subjects
GENETIC disorder treatment; THROMBOSIS prevention; DRUG efficacy; PERIOPERATIVE care; STATISTICS; INTRAVENOUS therapy; BLOOD coagulation tests; MULTIVARIATE analysis; INTRACRANIAL hemorrhage; CRITICALLY ill; MULTIPLE regression analysis; ANTICOAGULANTS; DIAPHRAGMATIC hernia; EXTRACORPOREAL membrane oxygenation; RETROSPECTIVE studies; TREATMENT duration; SURGICAL hemostasis; PATIENTS; SURGERY; FISHER exact test; SURGICAL complications; MEDICAL protocols; COMPARATIVE studies; FIBRIN; T-test (Statistics); RESEARCH funding; DESCRIPTIVE statistics; HEPARIN; DATA analysis software; HEMORRHAGE; EVALUATION; CHILDREN
- Publication
Perfusion, 2023, Vol 38, Issue 3, p507
- ISSN
0267-6591
- Publication type
Article
- DOI
10.1177/02676591211063805